Advertisement

Edrecolomab

  • Giuseppe Tridente
Chapter

Abstract

Edrecolomab (Panorex®, GSK) is a murine IgG2a monoclonal antibody derived from the original 17-1A murine mAb, and directed to the epithelial cell adhesion molecule EpCAM (EGP-2; CD326; 17-1A). Five anti-EpCAM monoclonal antibodies have been tested in cancer patients: murine edrecolomab, its chimeric IgG1 antibody version, the humanized and the fully human IgG1 antibodies (3622W94 and ING-1, respectively), and adecatumumab (MT201). None of them have shown to be effective as anti-neoplastic biomedicines. EpCAM is one of the first identified tumor-associated antigens expressed on human colon adenocarcinoma. However, EpCAM is also expressed by pancreatic, prostate, breast, kidney, lung, and ovarian tumors. It has also been selected as target of antitumoral vaccines.

Keywords

Ovarian Tumor Effector Capacity Human Colon Adenocarcinoma IgG2 Molecule EpCAM Expression 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. 1.
    Schmall H-J, Arnold D (2009) When wishful thinking leads to a misty-eyed appraisal: the story of the adjuvant colon cancer trials with edrecolomab. J Clin Oncol 27:1926–1929CrossRefGoogle Scholar
  2. 2.
    Niedzwiecki D, Bertagnolli MM, Warren RS et al (2011) Documenting the natural history of patients with resected stage II adenocarcinoma of the colon after random assignment to adjuvant treatment with edrecolomab or observation: results from CALGB 9581. J Clin Oncol 29:3146–3152PubMedCrossRefGoogle Scholar
  3. 3.
    Munz M, Murr A, Kvesic M et al (2010) Side-by-side analysis of five clinically tested anti-EpCAM monoclonal antibodies. Cancer Cell Int 10:44–55PubMedCrossRefGoogle Scholar
  4. 4.
    Gires O, Bauerle PA (2010) EpCAM as target in cancer therapy. J Clin Cancer 28:e239–240Google Scholar
  5. 5.
    Seimetz D (2011) Novel monoclonal antibodies for cancer treatment: the trifunctional antibody catumaxomab (Removab ®). J Cancer 2:309–316PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Italia 2014

Authors and Affiliations

  1. 1.University of VeronaVeronaItaly

Personalised recommendations